Lupin's Aurangabad facility gets zero adverse observations in US FDA's latest inspection

24 Apr 2024 , 11:33 AM

Lupin Limited announced on Tuesday that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Aurangabad manufacturing facility.

The inspection took place from March 6 to March 15, 2024, and the U.S. FDA classified the facility as Voluntary Action Indicated (VAI).

Currently, Lupin shares are trading at ₹1586.90, reflecting a 0.43% increase compared to the previous close. Over the past year, the stock has surged by a total of 126%. Since the beginning of the current year, Lupin’s stock has risen by 20.87%.

Nilesh Gupta, Managing Director of Lupin, expressed pleasure at receiving the EIR with VAI status, highlighting the company’s commitment to maintaining high compliance standards and delivering quality healthcare solutions globally.

Additionally, Lupin disclosed in a regulatory filing that a meeting of the Board of Directors is scheduled for Monday, May 6, 2024, to discuss and approve the audited financial results for the quarter and year-ended March 31, 2024, and to consider recommending dividends, if applicable.

For feedback and suggestions, write to us at [e-mail]